X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-10-02 | VYGR | Fahey Sandell Jacquelyn | GC | S - Sale | $5.82 | -5,999 | 86,001 | -7% | -$34,914 | ||||||
2024-04-02 | VYGR | Swartz Robin | COO | S - Sale | $9.88 | -1,357 | 117,004 | -1% | -$13,407 | ||||||
2024-04-02 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale | $9.86 | -12,115 | 322,839 | -4% | -$119,454 | ||||||
2024-02-21 | VYGR | Swartz Robin | COO | S - Sale | $7.45 | -3,966 | 118,361 | -3% | -$29,547 | ||||||
2024-02-21 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale | $7.46 | -13,033 | 334,954 | -4% | -$97,226 | ||||||
2024-02-21 | VYGR | Pfreundschuh Peter P. | CFO | S - Sale | $7.46 | -3,764 | 175,669 | -2% | -$28,079 | ||||||
| M | 2024-02-20 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.50 | -3,967 | 87,627 | -4% | -$29,760 | |||||
2024-01-17 | VYGR | Swartz Robin | COO | S - Sale | $7.15 | -2,543 | 72,327 | -3% | -$18,182 | ||||||
2024-01-17 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.18 | -1,266 | 53,094 | -2% | -$9,090 | ||||||
2023-10-03 | VYGR | Pfreundschuh Peter P. | CFO | S - Sale | $6.99 | -13,567 | 149,433 | -8% | -$94,833 | ||||||
| D | 2023-09-15 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $8.16 | -10,500 | 54,360 | -16% | -$85,680 | |||||
2023-07-06 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $10.80 | -5,500 | 59,860 | -8% | -$59,400 | ||||||
| D | 2023-06-30 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $11.41 | -5,000 | 65,360 | -7% | -$57,050 | |||||
2023-04-03 | VYGR | Sandrock Alfred | Pres, CEO | S - Sale | $7.83 | -7,437 | 214,618 | -3% | -$58,232 | ||||||
2023-04-03 | VYGR | Swartz Robin | COO | S - Sale | $7.83 | -1,259 | 71,617 | -2% | -$9,858 | ||||||
2023-03-20 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.76 | -2,193 | 65,360 | -3% | -$17,018 | ||||||
2023-03-20 | VYGR | Swartz Robin | COO | S - Sale | $7.76 | -3,654 | 72,876 | -5% | -$28,355 | ||||||
2023-03-20 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $7.76 | -4,410 | 102,200 | -4% | -$34,222 | ||||||
2023-03-15 | VYGR | Swartz Robin | COO | S - Sale | $8.20 | -15,373 | 76,530 | -17% | -$126,059 | ||||||
2023-02-23 | VYGR | Neurocrine Biosciences Inc | 10% | P - Purchase | $8.88 | +4,395,588 | 8,575,316 | +105% | +$39,032,821 | ||||||
2023-02-17 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $7.45 | -3,297 | 106,610 | -3% | -$24,563 | ||||||
| D | 2023-02-17 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $7.45 | -738 | 67,553 | -1% | -$5,498 | |||||
2023-02-13 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $7.67 | -797 | 34,291 | -2% | -$6,113 | ||||||
2023-02-13 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $7.67 | -2,868 | 109,907 | -3% | -$21,998 | ||||||
| M | 2023-01-30 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.23 | -388,642 | 4,721,992 | -8% | -$3,587,443 | |||||
2023-01-27 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.02 | -50,000 | 5,110,634 | -1% | -$451,000 | ||||||
| M | 2023-01-24 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.25 | -150,000 | 5,160,634 | -3% | -$1,388,000 | |||||
| M | 2023-01-20 | VYGR | Third Rock Ventures Iii, L.P. | 10% | S - Sale | $9.12 | -155,000 | 5,310,634 | -3% | -$1,413,300 | |||||
2023-01-17 | VYGR | Hesslein Robert W. | SVP, GC | S - Sale | $9.85 | -2,188 | 112,775 | -2% | -$21,549 | ||||||
2023-01-17 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $9.85 | -1,106 | 35,088 | -3% | -$10,892 | ||||||
2023-01-17 | VYGR | Swartz Robin | COO | S - Sale | $9.85 | -2,188 | 51,903 | -4% | -$21,549 | ||||||
| M | 2023-01-09 | VYGR | Ecor1 Capital, LLC | 10% | S - Sale | $7.91 | -902,400 | 3,851,507 | -19% | -$7,142,343 | |||||
2023-01-06 | VYGR | Carter Todd Alfred | Chief Scientific Officer | S - Sale | $6.41 | -388 | 36,194 | -1% | -$2,487 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |